Yu Rim Lee

Discordant Antitumor Efficacy with Compromised Survival in High-Risk Unresectable Hepatocellular Carcinoma

Background/Objectives: Real-world data in high-risk patients remain limited; this study evaluated survival, safety, and prognostic factors in this patient group. Methods: This multicenter study retrospectively reviewed 783 patients who received Ate/Bev from 2022–2024 across South...